source
- FDA rejects Hengrui-Elevar liver cancer drug combo for third time over manufacturing issuesFDA has again turned down a liver cancer drug combination from Jiangsu Hengrui Pharmaceuticals and Elevar Therapeutics. This is the third rejection in roughly two years, with the agency citing per…
- US biotech firms grow more secretive amid rising competition from Chinese industryUS biotech companies are becoming more secretive as competition from China’s rapidly expanding biotech sector intensifies. Janine Sengstack, a senior scientist at Junevity, says her team may have…